Ocular Therapeutix, Inc financial data

Symbol
OCUL on Nasdaq
Industry
Pharmaceutical Preparations
Location
15 Crosby Drive, Bedford, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
I-THERAPEUTIX INC (to 7/2/2009)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.37K % +269%
Quick Ratio 7.83 % +15.7%
Debt-to-equity 46.4 % -94.9%
Return On Equity -56.8 % +88.1%
Return On Assets -38.8 % +18.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 157M shares +98%
Common Stock, Shares, Outstanding 157M shares +97.3%
Entity Public Float 406M USD +42.9%
Common Stock, Value, Issued 16K USD +100%
Weighted Average Number of Shares Outstanding, Basic 167M shares +110%
Weighted Average Number of Shares Outstanding, Diluted 167M shares +96.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 61.4M USD +6.45%
Research and Development Expense 103M USD +76.1%
Selling and Marketing Expense 40M USD -4.4%
General and Administrative Expense 54.1M USD +57.8%
Costs and Expenses 203M USD +45.4%
Operating Income (Loss) -141M USD -72.9%
Nonoperating Income (Expense) -33.1M USD -326%
Net Income (Loss) Attributable to Parent -174M USD -160%
Earnings Per Share, Basic -1.32 USD/shares -51.7%
Earnings Per Share, Diluted -1.09 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 427M USD +286%
Accounts Receivable, after Allowance for Credit Loss, Current 30.2M USD +28.2%
Inventory, Net 2.41M USD +6.56%
Assets, Current 473M USD +235%
Property, Plant and Equipment, Net 10.1M USD -19.6%
Operating Lease, Right-of-Use Asset 5.69M USD -17.1%
Assets 490M USD +202%
Accounts Payable, Current 4M USD +0.43%
Employee-related Liabilities, Current 11.1M USD +41.3%
Accrued Liabilities, Current 30.5M USD +5.41%
Contract with Customer, Liability, Current 190K USD -40.1%
Liabilities, Current 36.4M USD +3.69%
Contract with Customer, Liability, Noncurrent 14M USD -1.39%
Operating Lease, Liability, Noncurrent 5.59M USD -22.9%
Other Liabilities, Noncurrent 117K USD +10.4%
Liabilities 138M USD -10.5%
Retained Earnings (Accumulated Deficit) -843M USD -26.1%
Stockholders' Equity Attributable to Parent 352M USD +4383%
Liabilities and Equity 490M USD +202%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.9M USD -69.7%
Net Cash Provided by (Used in) Financing Activities 321M USD +411724%
Net Cash Provided by (Used in) Investing Activities -255K USD +92.5%
Common Stock, Shares Authorized 400M shares +100%
Common Stock, Shares, Issued 157M shares +97.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 287M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 429M USD +282%
Interest Paid, Excluding Capitalized Interest, Operating Activities 13M USD +1750%
Deferred Tax Assets, Valuation Allowance 184M USD +11.7%
Deferred Tax Assets, Gross 195M USD +15.5%
Operating Lease, Liability 8.46M USD -17.6%
Payments to Acquire Property, Plant, and Equipment 255K USD -92.5%
Lessee, Operating Lease, Liability, to be Paid 10.7M USD -21.6%
Property, Plant and Equipment, Gross 32M USD +17.9%
Operating Lease, Liability, Current 1.72M USD -8.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.67M USD -4.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.5M USD -5.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure -7.46%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.25M USD -33.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.71M USD +1.31%
Deferred Tax Assets, Operating Loss Carryforwards 121M USD +6.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.11M USD -22.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 920K USD +90.5%
Deferred Tax Assets, Net of Valuation Allowance 10.8M USD +174%
Share-based Payment Arrangement, Expense 30.2M USD +70.5%
Interest Expense 13.6M USD +91.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%